Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amgen Inc Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance


Tuesday, 23 Apr 2013 04:00pm EDT 

Amgen Inc announced that for fiscal 2013, it expects revenue to remain unchanged at $17.8 billion to $18.2 billion and expects Adjusted EPS to be above the midpoint of the range of $7.05-$7.35. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $18.07 billion for fiscal 2013.